Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report released on Thursday morning. The firm issued a sell rating on the stock.

Several other equities research analysts have also recently weighed in on SYRS. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Piper Sandler restated an “overweight” rating and set a $5.00 target price (down from $13.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, August 13th. TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright restated a “neutral” rating and set a $1.00 price objective (down from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $3.33.

Syros Pharmaceuticals Stock Down 6.9 %

NASDAQ SYRS opened at $0.27 on Thursday. Syros Pharmaceuticals has a 12 month low of $0.18 and a 12 month high of $8.17. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 1.97. The stock has a market cap of $7.24 million, a PE ratio of -0.09 and a beta of 1.59. The stock’s 50 day moving average is $1.89 and its 200 day moving average is $3.61.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same quarter in the previous year, the company posted ($1.35) earnings per share. Research analysts predict that Syros Pharmaceuticals will post -2.94 EPS for the current fiscal year.

Insider Transactions at Syros Pharmaceuticals

In other Syros Pharmaceuticals news, CEO Conley Chee bought 50,000 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was acquired at an average cost of $1.51 per share, for a total transaction of $75,500.00. Following the completion of the transaction, the chief executive officer now owns 72,504 shares in the company, valued at $109,481.04. This trade represents a 222.18 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jason Haas purchased 35,363 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was bought at an average price of $1.55 per share, for a total transaction of $54,812.65. Following the completion of the acquisition, the chief financial officer now owns 59,915 shares of the company’s stock, valued at approximately $92,868.25. The trade was a 144.03 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 130,707 shares of company stock worth $206,491. 12.26% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Syros Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. GSA Capital Partners LLP bought a new stake in shares of Syros Pharmaceuticals in the third quarter valued at about $34,000. Virtu Financial LLC bought a new stake in shares of Syros Pharmaceuticals in the 1st quarter valued at about $64,000. Acadian Asset Management LLC purchased a new stake in shares of Syros Pharmaceuticals in the 1st quarter worth approximately $91,000. Certuity LLC bought a new position in shares of Syros Pharmaceuticals during the second quarter valued at approximately $109,000. Finally, Kennedy Capital Management LLC purchased a new position in Syros Pharmaceuticals during the first quarter valued at approximately $2,166,000. 91.47% of the stock is currently owned by hedge funds and other institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.